Avecho Recommences Final Stage of Phase III Insomnia Trial
Key points
- Recruitment for final stage of Phase III trial has recommenced
- Approximately 320 additional participants will be enrolled
- Independent Data Monitoring Board recommended continuing trial at planned size
Full summary
Avecho Biotechnology Limited has announced the recommencement of recruitment for the final stage of its pivotal Phase III clinical trial evaluating its TPM-enhanced cannabidiol (CBD) capsule for insomnia. Approximately 320 additional participants will be enrolled to reach the trial's planned size of 519 participants. This follows a positive interim analysis in June 2026, where the independent Data Monitoring Board recommended continuing the trial without increasing the sample size, indicating the study is appropriately sized. Recruitment has recommenced through existing clinical sites, with additional sites being activated to accelerate enrolment. Avecho expects to complete recruitment within approximately 12 months.
Guidance
No specific financial guidance provided.
Outlook
Avecho anticipates completing recruitment for the final stage of the Phase III trial within approximately 12 months.
Summary generated by a large language model. Please interpret with care.